Agnieszka Kowalska

Research activity per year

Fingerprint

Dive into the research topics where Agnieszka Kowalska is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

4 Active
12 Finished

EFC17504 A Randomized Double-blind Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis
Coyle, P. K. (PI), Kowalska, A. (CoPI), Polito, K. (CoPI), McLinskey, N. (CoPI) & Melville, P. (CoPI)
Sanofi US Services Incorporated
04/9/24 → 10/25/26
Stony Brook University
Project: Research
An Interventional, Phase 3 Extension Study to Investigate Long-Term Safety and Tolerability of Tolebrutinib in Participants with Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis of Nonrelapsing Secondary Progressive Mult
Coyle, P. K. (PI), Kowalska, A. (CoPI), McLinskey, N. (CoPI) & Melville, P. (CoPI)
Sanofi US Services Incorporated
03/12/24 → 10/25/26
Stony Brook University
Project: Research
Genentech: A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis
Coyle, P. K. (PI), Kowalska, A. (CoPI), McLinskey, N. (CoPI), Melville, P. (CoPI) & Syritsyna, O. (CoPI)
Syneos Health LLC
06/1/21 → 01/6/27
Stony Brook University
Project: Research
A Phase III Clinical Trial Evaluating DCVax-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)
Davis, R. (PI), Gutman, F. (CoPI), Kowalska, A. (CoPI), Galler, R. (CoPI), Rosiello, A. (CoPI) & Woo, H. (CoPI)
Northwest Biotherapeutics
07/12/13 → 09/3/26
Stony Brook University
Project: Research
NeuroNext: Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker in Subjects with Newly Diagnosed Primary Glioblastoma Multiforme
Kowalska, A. (PI) & Coyle, P. K. (CoPI)
National Inst of Neurological Disorders & Stroke
12/21/16 → 07/20/18
Stony Brook University
Project: Research

2 Article

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial
Griguer, C. E., Oliva, C. R., Coffey, C. S., Cudkowicz, M. E., Conwit, R. A., Gudjonsdottir, A. L., Ecklund, D. J., Fedler, J. K., Neill-Hudson, T. M., Nabors, L. B., Benge, M., Hackney, J. R., Chase, M., Leonard, T. P., Patel, T., Colman, H., De La Fuente, M., Chaudhary, R., Marder, K. & Kreisl, T. & 13 others, Mohile, N., Chheda, M. G., Mcneill, K., Kumthekar, P., Dogan, A., Drappatz, J., Puduvalli, V., Kowalska, A., Graber, J., Gerstner, E., Clark, S., Salacz, M. & Markert, J., Jan 1 2022, In: Neuro-Oncology Advances. 4, 1, vdab186.
Stony Brook University
Research output: Contribution to journal › Article › peer-review

Open Access
5 Scopus citations
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Cloughesy, T. F., Brenner, A., De Groot, J. F., Butowski, N. A., Zach, L., Campian, J. L., Ellingson, B. M., Freedman, L. S., Cohen, Y. C., Lowenton-Spier, N., Rachmilewitz Minei, T., Fain Shmueli, S., Avgeropoulos, N., Beck, J., Benkers, T., Bokstein, F., Brenner, A., Burton, E., Carrillo, J. & De Groot, J. & 37 others, De Robles, P., Drappatz, J., Dunbar, I., Fink, K., Groves, M., Han, X., Adila, H., Jensen, R., Kowalska, A., Kumthekar, P., Lee, M., Lesser, G., Lossos, A., Lukas, R., Macdonald, D., Mammoser, A., Mechtler, L., Mohile, N., Nagpal, S., Nicholas, G., Kreisl, T., Pan, E., Peak, S., Pearlman, M., Perry, J., Peterson, R., Piccioni, D., Robins, H., Ronan, L., Salacz, M., Schiff, D., Tran, D., Zach, L., Tzuk-Shina, T., Walbert, T., Wen, P. Y. & Youst, S., May 15 2020, In: Neuro-Oncology. 22, 5, p. 705-717 13 p.
Stony Brook University, Upstate Medical University
Research output: Contribution to journal › Article › peer-review

Open Access
65 Scopus citations

Agnieszka Kowalska

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

EFC17504 A Randomized Double-blind Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis

An Interventional, Phase 3 Extension Study to Investigate Long-Term Safety and Tolerability of Tolebrutinib in Participants with Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis of Nonrelapsing Secondary Progressive Mult

Genentech: A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis

A Phase III Clinical Trial Evaluating DCVax-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

NeuroNext: Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker in Subjects with Newly Diagnosed Primary Glioblastoma Multiforme

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Agnieszka Kowalska

Fingerprint

Collaborations and top research areas from the last five years

Grants & Projects

EFC17504 A Randomized Double-blind Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis

An Interventional, Phase 3 Extension Study to Investigate Long-Term Safety and Tolerability of Tolebrutinib in Participants with Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis of Nonrelapsing Secondary Progressive Mult

Genentech: A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis

A Phase III Clinical Trial Evaluating DCVax-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

NeuroNext: Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker in Subjects with Newly Diagnosed Primary Glioblastoma Multiforme

Research output

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)